Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
SOM-401 by Inflammasome Therapeutics for Geographic Atrophy: Likelihood of Approval
SOM-401 is under clinical development by Inflammasome Therapeutics and currently in Phase I for Geographic Atrophy. According to GlobalData, Phase...